New COVID cases cross 3 lakh after eight months; Omicron case tally rises to 9,287

New Delhi: India logged 3,17,532 COVID cases and 491 deaths in the last 24 hours, highest in over 249 days. The last time cases in India crossed three lakhs was eight months ago on May 15, 2021. The Omicron tally for the country has also risen to 9,287.

The cumulative vaccine coverage crossed 159.67 Crore in the country with the administration of over 73 lakh doses in the last 24 hours. Over 61 lakh precaution doses have now been administered under the programme started for vulnerable groups on January 10. Meanwhile, over 3.8 Crore children in the age group of 15-18 years or more than 50 per cent have received their first dose of Covaxin.

With several states reporting a rise in daily COVID cases, the active cases mounted to 19,24,051 which is the highest in over 233 days. 2,23,990 recoveries in the last 24 hours takes the recovery rate to 93.69 per cent, which has witnessed a consistent drop since the onset of the third wave. The daily positivity rate stood at 16.41 percent while the weekly positivity rate has risen to 16.06 percent.

Kerala on Wednesday recorded a sharp spike with 34,199 cases being reported with the positivity rate jumping to 37.17 in the state. Health minister Veena George on Wednesday said that both Omicron and Delta variants have been driving the surge in cases and three weeks remain critical for the state. Assam, Gujarat were amongst the other states setting daily cases record. Delhi’s positivity rate on contrast has declined to 23.86 percent with 13,785 new cases on Wednesday.

The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has recommended full market approval for both Covishield and Covaxin after reviewing data from phase 1, 2 and 3 clinical trials of the vaccine. The vaccines made by Serum Institute of India (SII) and Bharat Biotech have till now been granted Emergency Use Authorisation (EUA) and have been deployed in India’s COVID vaccination drive.

  • Related Posts

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Puresta launches EVERQ, AI-powered skin-health platform

    Puresta launches EVERQ, AI-powered skin-health platform

    Stem cell therapy for autism only in approved clinical trials: Centre

    Stem cell therapy for autism only in approved clinical trials: Centre